リンパ球とがん細胞を認識するヒト型二重特異性抗体  [in Japanese] Humanized bispecific antibodies retargeting of lymphocytes against tumor cells  [in Japanese]

Access this Article

Author(s)

    • 熊谷 泉 KUMAGAI Izumi
    • 東北大学大学院工学研究科バイオ工学専攻 Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University
    • 浅野 竜太郎 ASANO Ryutaro
    • 東北大学大学院工学研究科バイオ工学専攻 Department of Biomolecular Engineering, Graduate School of Engineering, Tohoku University

Abstract

液性免疫を担う主たる分子である抗体は,高い特異性と親和性ゆえに,分析試薬,診断薬のみならず,医薬としても開発されている.すでにFDAに20品目以上認可されており,100品目以上臨床研究に入っているともされるが,効果が不充分であったり,生産コスト高が問題となっている.そこで,ヒトあるいはヒト型化された抗体断片を用いた,より高機能な組換え抗体の研究が広く進められるようになった.本稿では,特にリンパ球とがん細胞を標的とした二重特異性抗体に焦点を絞り,新規な抗体医薬としてのがん治療への応用と展望を解説した.

Antibodies play a central role in humoral immunity and have been developed not only as reagents for the detection and diagnosis but also as clinical products due to its high affinity and specificity. Approximately 20 therapeutic antibodies have been approved by the FDA, and there are more than 100 additional antibodies in clinical development. In the development of antibody drugs, problems such as limited efficacy and high production costs have become so serious that attempts are now being made to construct highly effective and potent recombinant antibodies from human and/or humanized protein fragments. In this review, we focused on bispecific antibodies retargeting of lymphocytes against tumor cells and introduced its perspective as a novel reagent for cancer therapy.

Journal

  • Drug Delivery System

    Drug Delivery System 23(5), 518-525, 2008-09-30

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References:  23

Codes

  • NII Article ID (NAID)
    10024309899
  • NII NACSIS-CAT ID (NCID)
    AN10084591
  • Text Lang
    JPN
  • Article Type
    REV
  • ISSN
    09135006
  • NDL Article ID
    9661645
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-1945
  • Data Source
    CJP  NDL  J-STAGE 
Page Top